Multinational Observational Uncontrolled Open Programme "The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy"
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,247
- 试验地点
- 26
- 主要终点
- The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
研究概览
简要总结
The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy.
The main aim of this study to assess the antihypertensive effectiveness effect on the 24-hour BP profile, as well as tolerability of and compliance to the treatment with a triple FDC of amlodipine / indapamide / perindopril arginine in hypertensive patients in the real clinical practice.
Type of program: Multicenter, observational, non-controlled, open-label program.
Investigators: Cardiologists and outpatient (primary care) physicians (general practitioners).
Number of patients: 1,300 hypertensive patients.
详细描述
It is multicenter, observational, non-controlled, open-label program. The baseline characteristics will be analyzed in all the patients who started the treatment (intention-to-treat [ITT] population). In case of significant differences between two treatment groups, the baseline characteristics will be provided for both of them.
Changes in the SBP and DBP (with the corresponding confidence intervals) will be assessed in the patients who completed the program without major deviations from protocol (per-protocol population [PPP]).
The analysis of parameters with normal distribution will be performed using the Student's t-test for paired measurements; otherwise the non-parametric Wilcoxon test will be used. The percentage of patients with normalized BP, as well as the percentage of patients who responded to treatment (with 95% confidence intervals), will be calculated.
Questionnaires: The score for each scale will be calculated as the sum of scores for questions constituting the scale.
Assessment of the AEs will be carried out in all the patients who started the treatment (ITT population).
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 79 years
- •Essential hypertension
- •Patient's consent to participate in the program
- •Doctor's decision to prescribe FDC of amlodipine / indapamide / perindopril arginine, according to the instruction for use, prior to the inclusion in the program.
排除标准
- •Symptomatic, or secondary arterial hypertension
- •Office BP ≥ 180/110 mm Hg on treatment (at V0 visit)
- •History of myocardial infarction, unstable angina, or cerebrovascular accident within the past 1 year
- •CHF of class III-IV NYHA
- •Type I diabetes or decompensated type 2 diabetes
- •Diseases with severe organ dysfunction (hepatic failure, renal failure, etc.)
- •Contraindications to or known intolerance of dihydropyridine calcium channel blockers (including amlodipine) and/or indapamide and/or ACE inhibitors (including perindopril) and/or their fixed combination
- •Inability to understand the nature of the program and/or to follow the doctor's recommendations, including ones for the BP self-monitoring.
研究组 & 干预措施
Patients with arterial hypertension
The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.
Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.
干预措施: amlodipine / indapamide / perindopril arginine FDC (Drug)
结局指标
主要结局
The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
时间窗: Baseline, 3 months
Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position
The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline
时间窗: Baseline, 3 months
Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded.
次要结局
- The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline(Baseline, 3 months)
- The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline(Baseline, 3 months)
- Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline(Baseline, 3 months)